Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer

Qiao,En-Qi; Ji,Minghua; Wu,Jianzhong; Li,Jian; Xu,Xinyu; Ma,Rong; Zhang,Xiaohua; He,Yuejun; Zha,Quanbin; Song,Xue; Zhu,Liwei; Tang,Ji-Hai

doi:10.3892/mco.2013.111

Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer

Authors:
- En-Qi Qiao
- Minghua Ji
- Jianzhong Wu
- Jian Li
- Xinyu Xu
- Rong Ma
- Xiaohua Zhang
- Yuejun He
- Quanbin Zha
- Xue Song
- Liwei Zhu
- Ji-Hai Tang
View Affiliations

Affiliations: Department of General Surgery, Jiangsu Cancer Hospital, Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China, Department of Radiotherapy, Jiangsu Cancer Hospital, Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China, Research Center for Clinical Oncology, Jiangsu Cancer Hospital, Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China, Department of Pathology, Jiangsu Cancer Hospital, Affiliated to Nanjing Medical University, Nanjing, Jiangsu 210009, P.R. China, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China, Xuzhou Medical College, Xuzhou, Jiangsu 221000, P.R. China
Published online on: May 8, 2013 https://doi.org/10.3892/mco.2013.111
Pages: 703-710

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is one of the most common malignancies in women. This study was conducted to analyze the association between the expressions of eight immunohistochemical (IHC) indices and clinicopathological characteristics in breast cancers (BCs) and investigate the clinical significance. IHC Envision ldpe‑g‑nvp was used to detect the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), p53, type II topoisomerase (TOPO II) and Ki‑67 in postoperative paraffin blocks of 286 cases of invasive BC and statistically analyzed their correlations with clinicopathological characteristics. The positive rates of ER, PR, HER2, VEGF, p53, EGFR, TOPO II and Ki‑67 expression were 62.24, 41.96, 57.34, 53.85, 81.82, 46.85, 54.55 and 69.93%, respectively. ER expression was negatively correlated with age, tumor size and histological grade (P<0.05) and PR expression was negatively correlated with age and histological grade (P<0.05). Among the ER, PR and c‑erbB‑2 statuses, a significant correlation was observed between ER expression and PR status (P=0.0000), whereas the expression of ER and PR exhibited a negative correlation with HER2 status (P<0.05). We also demonstrated a significant correlation between EGFR expression and lymph node metastasis (P=0.0240), p53 expression and tumor size (P=0.0300), p53 and Ki‑67 expression and histological grade (P<0.05) and the expressions of VEGF, EGFR, p53, TOPO II, Ki‑67 and HER2 status (P<0.05). In addition, the Luminal B and Her2/neu subtypes exhibited a close correlation with age (P<0.01), while the Her2/neu and triple‑negative subtypes were positively correlated with poor histological grade (P<0.05). In conclusion, there is a definite correlation between IHC indices and clinicopathological characteristics in BCs. Combined detection of these indices may be significant in the evaluation of biological behavior and prognosis of BC and thus in the diagnosis and comprehensive treatment of this disease.

View Figures

View References

1.	Liu C, Zhang H, Shuang C, Lu Y, Jin F, Xu H and Lu P: Alterations of ER, PR, HER-2/neu, and P53 protein expression in ductal breast carcinomas and clinical implication. Med Oncol. 27:747–752. 2010. View Article : Google Scholar : PubMed/NCBI
2.	Hicks DG and Kulkarni S: HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 129:263–273. 2008.
3.	Recăreanu F, Simionescu C, Georgescu CV and Pirici E: Ductal invasive mammary carcinoma - clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein. Rom J Morphol Embryol. 52:1059–1064. 2011.
4.	Woolcott CG, SenGupta SK, Hanna WM and Aronson KJ: Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy-controls. BMC Cancer. 8:1302008. View Article : Google Scholar
5.	Walker RA: Immunohistochemical markers as predictive tools for breast cancer. J Clin Pathol. 61:689–696. 2008. View Article : Google Scholar : PubMed/NCBI
6.	Wang ZB, Zhao P, Liu M and Li XH: Expression of ER, PR and Cyclin D1 in breast infiltrating ductal carcinoma and their clinicopathological significance. Zhonghua Yi Xue Za Zhi. 85:514–517. 2005.(In Chinese).
7.	Wu X, Zhang X, Zhang H, et al: Progesterone receptor down-regulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer. Cancer Sci. 103:959–967. 2012. View Article : Google Scholar : PubMed/NCBI
8.	Daniel AR, Hagan CR and Lange CA: Progesterone receptor action: defining a role in breast cancer. Expert Rev Endocrinol Metab. 6:359–369. 2011. View Article : Google Scholar : PubMed/NCBI
9.	Wargon V, Fernandez SV, Goin M, et al: Hypermethylation of the progesterone receptor A in constitutive antiprogestin-resistant mouse mammary carcinomas. Breast Cancer Res Treat. 126:319–332. 2011. View Article : Google Scholar : PubMed/NCBI
10.	Gown AM: Current issues in ER and HER-2 testing by IHC in breast cancer. Mod Pathol. 21(Suppl 2): S8–S15. 2008. View Article : Google Scholar : PubMed/NCBI
11.	Guo H and Bai O: Relationship between the expression of ER, PR, Her -2 in breast cancer and its clinical pathological features. Chin J Lab Diagn. 12:1390–1392. 2008.
12.	Bagaria SP, Ray PS, Wang J, et al: Prognostic value of basal phenotype in HER2-overexpressing breast cancer. Ann Surg Oncol. 19:935–940. 2012. View Article : Google Scholar : PubMed/NCBI
13.	Schillaci R, Guzmán P, Cayrol F, et al: Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer. 12:742012. View Article : Google Scholar : PubMed/NCBI
14.	Hussein MR, Abd-Elwahed SR and Abdulwahed AR: Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncegene protein expression in ductal carcinomas of the breast. Cell Biol Int. 32:698–707. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Taucher S, Rudas M, Mader RM, et al: Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer. 98:2547–2553. 2003. View Article : Google Scholar : PubMed/NCBI
16.	Prat A and Baselga J: The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol. 5:531–542. 2008. View Article : Google Scholar : PubMed/NCBI
17.	Murthy SS, Sandhya DG, Ahmed F, et al: Assessment of HER2/Neu status by fluorescence in situ hybridization in immunohistochemistry-equivocal cases of invasive ductal carcinoma and aberrant signal patterns: a study at a tertiary cancer center. Indian J Pathol Microbiol. 54:532–538. 2011. View Article : Google Scholar
18.	Kowanetz M and Ferrara N: Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 12:5018–5022. 2006. View Article : Google Scholar : PubMed/NCBI
19.	Zhao YC, Ni XJ, Wang MH, Zha XM, Zhao Y and Wang S: Tumor-derived VEGF-C, but not VEGF-D, promotes sentinel lymph node lymphangiogenesis prior to metastasis in breast cancer patients. Med Oncol. 29:2594–2600. 2012. View Article : Google Scholar : PubMed/NCBI
20.	Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R and Bergh J: The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res. 61:2256–2260. 2001.PubMed/NCBI
21.	Jobim FC, Schwartsmann G, Xavier NL, et al: Expression of MMP-9 and VEGF in breast cancer: correlation with other prognostic indicators. Rev Bras Ginecol Obstet. 30:287–293. 2008.(In Portuguese).
22.	Linderholm BK, Hellborg H, Johansson U, et al: Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol. 20:1639–1646. 2009. View Article : Google Scholar
23.	Burness ML, Grushko TA and Olopade Ol: Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J. 16:23–32. 2010. View Article : Google Scholar : PubMed/NCBI
24.	Kallel I, Khabir A, Boujelbene N, et al: EGFR overexpression relates to triple negative profile and poor prognosis in breast cancer patients in Tunisia. J Recept Signal Transduct Res. 32:142–149. 2012. View Article : Google Scholar : PubMed/NCBI
25.	Viale G, Rotmensz N, Maisonneuve P, et al: Invasive ductal carcinoma of the breast with the ‘triple-negative’ phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 116:317–328. 2009.
26.	Skobe M, Hawighorst T, Jackson DG, et al: Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med. 7:192–198. 2001. View Article : Google Scholar : PubMed/NCBI
27.	Kazemi M, Salehi Z and Chakosari RJ: TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol Res. 18:25–30. 2009. View Article : Google Scholar : PubMed/NCBI
28.	Dookeran KA, Dignam JJ, Ferrer K, et al: p53 as a marker of prognosis in African-American women with breast cancer. Ann Surg Oncol. 17:1398–1405. 2010. View Article : Google Scholar : PubMed/NCBI
29.	González-Rodilla I, Verna V, Muñoz AB, Estévez J, Boix M and Schneider J: Expression of the apoptosis-related genes Bcl-2 and p53 in clinical samples from endometrial carcinoma patients. Anticancer Res. 31:4191–4193. 2011.PubMed/NCBI
30.	Mao XY, Fan CF, Zheng HC, Wei J, Yao F and Jin F: p53 nuclear accumulation and ERalpha expression in ductal hyperplasia of breast in a cohort of 215 Chinese women. J Exp Clin Cancer Res. 29:1122010. View Article : Google Scholar : PubMed/NCBI
31.	Tokiniwa H, Horiguchi J, Takata D, et al: Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Breast Cancer. 19:309–314. 2012. View Article : Google Scholar
32.	Tanner B, Pilch H, Schäffer U, et al: Expression of c-erbB-2 and topoisomerase II alpha in relation to chemoresistance in ovarian cancer. Zentralbl Gynakol. 124:176–183. 2002.(In German).
33.	Urruticoechea A, Smith IE and Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
34.	de Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 96:1504–1513. 2007.PubMed/NCBI
35.	Dowsett M, Nielsen TO, A’hern R, et al: Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 103:1656–1664. 2011. View Article : Google Scholar : PubMed/NCBI
36.	Endo Y, Toyama T, Takahashi S, et al: High estrogen receptor expression and low Ki67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol. 16:512–518. 2011. View Article : Google Scholar : PubMed/NCBI
37.	Cheang MC, Chia SK, Voduc D, et al: Ki67 index, HER2 status, and prognosis of patients with Luminal B breast cancer. J Natl Cancer Inst. 101:736–750. 2009. View Article : Google Scholar
38.	Xue C, Wang X, Peng R, et al: Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci. 103:1679–1687. 2012. View Article : Google Scholar : PubMed/NCBI
39.	Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S and Cooper K: Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients. Asian Pac J Cancer Prev. 10:773–778. 2009.PubMed/NCBI
40.	Moriya T, Kanomata N, Kozuka Y, et al: Molecular morphological approach to the pathological study of development and advancement of human breast cancer. Med Mol Morphol. 43:67–73. 2010. View Article : Google Scholar : PubMed/NCBI